July 23, 2009 – Symphony Medical Inc., a development-stage company focused on novel biopolymer implant therapies to treat cardiac abnormalities, said yesterday it changed the name of the corporation to CardioPolymers Inc.
"The name change, which is effective immediately, better reflects our focus on employing natural biocompatible polymer implants to treat cardiac patients - specifically, congestive heart failure patients with an enlarged left ventricle,” said CardioPolymers CEO Raymond W. Cohen.
CardioPolymers is currently sponsoring a human clinical study of its patented flagship technology Algisyl-LVR at world-class centers in Europe, including the German Heart Center in Munich where the first three patients were successfully treated.
Algisyl-LVR is an implantable medical device under clinical development intended to prevent or reverse the progression of congestive heart failure in patients with dilated cardiomyopathy, a condition in which the heart becomes weakened and enlarged, and cannot pump blood efficiently. The procedure involves injecting a proprietary biopolymer directly into strategic locations of the heart's left ventricle wall. As it is injected, the biopolymer thickens and forms firm, gel-like structures that remain in the heart muscle as permanent implants. These implants act to reshape the heart, reduce the size of the dilated left ventricle and thicken the damaged wall of the heart, thus returning the heart to a healthier form that facilitates improved cardiac function and performance.
For more information: www.symphonymed.com
April 25, 2024 
